Article
The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
Cancer medicine - 1 Feb 2021
Altman Jessica K, Perl Alexander E, Hill Jason E, Rosales Matt, Bahceci Erkut, Levis Mark J
Abstract excerpt
The FLT3 inhibitor gilteritinib has clinical activity in patients with FLT3-mutated (FLT3mut+ ) relapsed/refractory (R/R) acute myeloid leukemia (AML). The impact of FLT3 mutation clearance and the achievement of composite complete remission (CRc) and complete remission/complete remission with partial hematologic recovery (CR/CRh) on overall survival (OS) in patients with FLT3mut+ R/R AML treated with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.